베바시주맙 시장 : 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global bevacizumab market size is expected to reach USD 18.46 Billion in 2034 from USD 7.66 Billion in 2025, growing at a CAGR of 10.26 during 2026-2034.This market is experiencing significant growth driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Bevacizumab is a monoclonal antibody used in the treatment of various cancers, including colorectal, lung, and breast cancer. Its ability to inhibit angiogenesis, the formation of new blood vessels that feed tumors, has made it a crucial component in oncology treatment. The growing focus on personalized medicine and advanced cancer therapies is further boosting market demand.

Key drivers include advancements in biotechnology and increasing investments in cancer research and development. The rising adoption of biosimilars is also contributing to market expansion by making treatments more accessible and affordable. Additionally, the growing healthcare infrastructure and improved diagnostic capabilities are enabling early detection and treatment of cancer, increasing the use of bevacizumab. Government initiatives and funding for cancer treatment programs are further supporting market growth.

Looking ahead, the market is expected to benefit from ongoing research and the development of new therapeutic applications. The expansion of biosimilar products will enhance accessibility and reduce treatment costs. Emerging markets are anticipated to witness significant growth due to increasing healthcare investments and awareness. As the global burden of cancer continues to rise, the bevacizumab market is set to play a critical role in advancing oncology treatment and improving patient outcomes.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Avastin
• Alymsys
• Mvasi
• Others

By Indication

• Metastatic Colorectal Cancer
• Recurrent Glioblastoma
• Metastatic Renal Cell Carcinoma
• Persistent, Recurrent, or Metastatic Cervical Cancer
• Others

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies and Drug Stores
• Others

COMPANIES PROFILED

• Genentech Inc. (F. Hoffmann-La Roche Ltd), Pfizer Inc., Amneal Pharmaceuticals LLC., Novartis AG, Amgen Inc., Celltrion Healthcare Co. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BEVACIZUMAB MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Avastin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Alymsys Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Mvasi Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BEVACIZUMAB MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Metastatic Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Recurrent Glioblastoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metastatic Renal Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Persistent, Recurrent, or Metastatic Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BEVACIZUMAB MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channels
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies and Drug Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BEVACIZUMAB MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channels
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channels
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channels
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channels
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channels
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BEVACIZUMAB INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc. (F. Hoffmann-La Roche Ltd)
  • 9.2.2 Pfizer Inc
  • 9.2.3 Amneal Pharmaceuticals LLC
  • 9.2.4 Novartis AG
  • 9.2.5 Amgen Inc
  • 9.2.6 Celltrion Healthcare Co. Ltd